M
Mid Atlantic Retina | Bethlehem, PA
Research site
(Unclaimed)
Site insights
Top conditions
Top treatments
Pegcetacoplan
APL-2
CU06-1004
Tarcocimab
Parent organization
This site is a part of Mid Atlantic Retina
Data sourced from clinicaltrials.gov
Work at this site?
CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.
Active trials
3 of 5 total trials
This study will demonstrate that tarcocimab 5 mg is superior to sham treatment in participants with moderately severe to severe NPDR.
Enrolling
Non-proliferative Diabetic Retinopathy
Drug: Tarcocimab
Other: Sham injection
This is a phase 3, open-label, multicenter, extension study to evaluate the long-term safety and efficacy of pegcetacoplan (APL-2) in subjects with g...
Active, not recruiting
Geographic Atrophy Secondary to Age-related Macular Degeneration
Drug: PEGCETACOPLAN (APL-2)
In this study researchers want to learn more about changes in visual acuity (clarity of vision) with a high dose treatment with Aflibercept (Eylea) i...
Active, not recruiting
Neovascular Age-Related Macular Degeneration
Drug: Aflibercept VEGF Trap-Eye (Eylea, BAY86-5321)
Drug: Aflibercept High Dose VEGF Trap-Eye (BAY86-5321)
Trial sponsors
A
C
Clinical trials
Research sites
Resources
Legal
© Copyright 2024 Veeva Systems